Compare Japan Tissue Engineering Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0.47%
- The company has been able to generate a Return on Equity (avg) of 0.47% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -357.39
3
Poor long term growth as Net Sales has grown by an annual rate of 0.64% and Operating profit at -19.88% over the last 5 years
4
The company has declared positive results in Jun'2026 after 4 consecutive negative quarters
5
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
JPY 25,463 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.64
-11.49%
5.00
Revenue and Profits:
Net Sales:
767 Million
(Quarterly Results - Jun 2026)
Net Profit:
52 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
32.05%
0%
32.05%
6 Months
47.48%
0%
47.48%
1 Year
52.13%
0%
52.13%
2 Years
59.84%
0%
59.84%
3 Years
51.01%
0%
51.01%
4 Years
33.55%
0%
33.55%
5 Years
19.19%
0%
19.19%
Japan Tissue Engineering Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.64%
EBIT Growth (5y)
-19.88%
EBIT to Interest (avg)
-373.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.42
Tax Ratio
0.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.59%
ROE (avg)
0.47%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.55
EV to EBIT
-43.90
EV to EBITDA
-66.10
EV to Capital Employed
10.67
EV to Sales
9.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-24.30%
ROE (Latest)
-8.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
766.80
673.10
13.92%
Operating Profit (PBDIT) excl Other Income
92.80
52.90
75.43%
Interest
0.00
0.00
Exceptional Items
0.00
-150.00
100.00%
Consolidate Net Profit
52.20
-178.60
129.23%
Operating Profit Margin (Excl OI)
77.10%
20.50%
5.66%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 13.92% vs 31.75% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 129.23% vs 3.35% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
2,182.70
2,455.50
-11.11%
Operating Profit (PBDIT) excl Other Income
-399.20
-124.70
-220.13%
Interest
0.00
0.00
Exceptional Items
-150.00
0.00
Consolidate Net Profit
-734.80
-255.30
-187.82%
Operating Profit Margin (Excl OI)
-251.70%
-97.10%
-15.46%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -11.11% vs -2.33% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -187.82% vs -278.28% in Mar 2025
About Japan Tissue Engineering Co., Ltd. 
Japan Tissue Engineering Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






